Solid IO advances tumor-on-chip platform with clinical feasibility study in breast cancer

Building on the company’s published proof-of-concept in lung cancer, the study marks the next step in the clinical development of the Solid IO platform and expands its evaluation into breast cancer.

“This is an important milestone for Solid IO. We have already demonstrated the potential of our technology with patient-derived samples in lung cancer. Now we are taking the next step in breast cancer and building the clinical evidence needed to bring the platform closer to predictive testing,” says Noora Hujala, CEO of Solid IO.

Solid IO’s platform uses patient-derived tumor and immune cells to model the tumor microenvironment and measure individual responses to cancer therapies ex vivo. The technology is being developed to help predict treatment response in precision oncology and to provide more human-relevant models for oncology drug development.

Triple-negative breast cancer is an aggressive form of breast cancer where better tools are needed to understand and predict individual treatment responses. The new study will evaluate the feasibility of the Solid IO platform in a prospective clinical setting. The platform is being developed for applications across precision oncology and drug development, providing a human-relevant approach to studying tumor responses to cancer therapies.

“Our technology allows us to study treatment response in the context of each patient’s own tumor and immune biology. Expanding our work into breast cancer is an important step in understanding the platform’s potential across different cancers and ultimately in predicting individual treatment response,” says Heidi Haikala, PhD, Co-founder and Chief Scientific Officer of Solid IO.

The study is conducted at HUS Comprehensive Cancer Center, Finland’s largest cancer treatment and clinical cancer research center. Part of HUS Helsinki University Hospital, the center combines specialized cancer care with extensive clinical research and a strong focus on advancing personalized cancer treatment. The study is led by Johanna Mattson, Senior Medical Director and Director of HUS Comprehensive Cancer Center.

“There is a clear need for better tools to predict treatment response in triple-negative breast cancer. Functional approaches using patient-derived tumor models offer an interesting new method to assess individual treatment response,” says Johanna Mattson, Principal Investigator of the study at HUS Comprehensive Cancer Center.

The study represents an important step in the continued development of the Solid IO platform and in building evidence for its potential across oncology.

‍